I have the plan documents and the written criteria, which took two calls to obtain.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
Which parts of this are load-bearing and which parts are habit?
It helps to be literal here: potency variation between compounders is a manufacturing-control question rather than an integrity question, and it is the predictable consequence of preparing a potent peptide by hand at small scale.
Whether a telehealth prescription can be filled at a retail pharmacy depends on the prescription and the jurisdiction rather than on the modality: a prescription for a licensed product from a prescriber licensed in the patient’s jurisdiction is generally fillable anywhere that stocks it. A prescription written to a specific compounding pharmacy for a preparation only that pharmacy makes is not portable, and that non-portability is sometimes the commercial point.
| Line | Brand, insured | Compounded, subscription | Research-grade, self-tested |
|---|---|---|---|
| Product | Copay × 12 | Monthly fee × 12 | Vials × unit price |
| Consultation | Covered or copay | Bundled | Not applicable |
| Monitoring labs | Often covered | Usually not | Self-funded |
| Independent testing | Not applicable | Optional | Essential; per lot |
| Shipping | Pharmacy | Included | Per order |
| Dominant cost | Copay structure | Subscription fee | Testing |
Stated carefully, a beyond-use date for a compounded multi-dose preparation is set under USP chapter provisions on the basis of microbiological risk category and, where available, supporting stability data. In practice most beyond-use dates in this space are default values from the risk-category table rather than the output of a stability study, and the two should not be read as equivalent claims.
External review of health-plan denials in the United States operates under the Affordable Care Act’s appeal provisions and, for employer self-funded plans, under ERISA; the practical significance is that an independent reviewer applies the plan’s own criteria without the plan’s involvement.
Ask for the written criteria before you submit. Everything else in the process is easier once you have them.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsTo be exact about it, the salt-versus-base issue is worth understanding precisely because it is a genuine regulatory tell rather than a technicality.
Denials come in two flavours and it is worth identifying which you have. A criteria denial means the submission did not evidence something the criteria require, and it is fixed by supplying the evidence. A formulary exclusion means the plan does not cover the drug at any level for any indication, and no amount of clinical documentation changes it — the route there is a formulary exception request or an employer-level appeal.
Features of a defensible telehealth intake: a real history including contraindications and family history, a recorded weight and height rather than a self-attested figure, baseline laboratory work or a documented reason for its absence, a named prescriber you can identify and verify, a titration plan, and a mechanism for reporting adverse events that reaches a clinician. A checkbox intake that issues a prescription in four minutes has none of these.
Accreditation by the Pharmacy Compounding Accreditation Board or by ACHC is voluntary and verifiable, and verification is a matter of checking the accreditor’s register rather than accepting a logo on a website.
If the intake did not ask about contraindications, that tells you what kind of service it is.
It helps to be literal here: model the cost across the whole route, including the parts that are not the drug: consultation fees, laboratory monitoring, shipping, and the tests you will pay for yourself.
The salt-form point: the statutory pathway for compounding a copy of an approved drug during a shortage applies to the same active moiety as the approved product. A preparation described as a salt form — "semaglutide sodium", "semaglutide acetate" — is describing a different chemical entity from the approved base, and the description is usually there to construct an argument that it is not a copy. Whatever the legal merits, it means what is in the vial is not what was studied.
What a payer wants in a prior authorisation is documentation mapped to their own written criteria, in their own terms: a diagnosis code, a documented body mass index or comorbidity meeting their threshold, a record of a supervised lifestyle intervention over their specified duration, and documentation of any step-therapy agent tried and its outcome. A clinical narrative that does not map onto those fields will be denied by someone who never reads the narrative.
Model twelve months, not one. The fee structures are designed to be compared monthly.
edited 1 Jun 2026 by harriet_lonsdale — added the method parameters
Prior authorisation is an adjudication against written criteria, and the criteria are usually obtainable. Requesting them before submitting is the single highest-yield step in the process.
The internal-then-external appeal path is worth pursuing further than most people do, because the external reviewer is not the plan. Internal appeals are adjudicated by the entity that issued the denial; external review is conducted by an independent organisation against the same criteria, and it overturns a non-trivial fraction of denials.
Verify accreditation on the accreditor’s register rather than on the pharmacy’s website. It takes a minute.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.